Hydroxyhexamide

CAS No. 3168-01-2

Hydroxyhexamide( (±)-Hydroxyhexamid )

Catalog No. M17724 CAS No. 3168-01-2

Hydroxyhexamide is a pharmacologically active metabolite of Acetohexamide, used as a hypoglycemic agent.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 81 In Stock
5MG 133 In Stock
10MG 237 In Stock
25MG 402 In Stock
50MG 581 In Stock
100MG 799 In Stock
500MG 1611 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Hydroxyhexamide
  • Note
    Research use only, not for human use.
  • Brief Description
    Hydroxyhexamide is a pharmacologically active metabolite of Acetohexamide, used as a hypoglycemic agent.
  • Description
    Hydroxyhexamide is a pharmacologically active metabolite of Acetohexamide, used as a hypoglycemic agent.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    (±)-Hydroxyhexamid
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    PPAR
  • Recptor
    ATP-sensitive potassium (KATP) channels
  • Research Area
    Cardiovascular Disease
  • Indication
    ——

Chemical Information

  • CAS Number
    3168-01-2
  • Formula Weight
    326.41
  • Molecular Formula
    C15H22N2O4S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : ≥ 300 mg/mL; 919.09 mM
  • SMILES
    O=C(NC1CCCCC1)NS(=O)(=O)c2ccc(cc2)C(C)O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Imamura Y,etal.Hypoglycemic effect of S(-)-hydroxyhexamide, a major metabolite of acetohexamide, and its enantiomer R(+)-hydroxyhexamide.Life Sci. 2001 Sep 7;69(16):1947-55.
molnova catalog
related products
  • BAY-4931

    BAY-4931 is a powerful, covalent, and selective inverse-agonist of PPARγ, exhibiting an IC50 value of 0.17 nM.

  • Fonadelpar

    Fonadelpar (NPS-005,SJP-0035) is a potent, selective peroxisome proliferator activated receptor δ (PPARδ) agonist for the treatment of corneal disorders.

  • 1-Deoxynojirimycin

    1-Deoxynojirimycin is a potent α-glucosidase inhibitor, suppressing postprandial blood glucose, thereby possibly preventing diabetes mellitus.